Literature DB >> 12115332

Cognitive functioning and quality of life in long-term adult survivors of bone marrow transplantation.

Helena Harder1, Jan J Cornelissen, Arthur R Van Gool, Hugo J Duivenvoorden, Wil M H Eijkenboom, Martin J van den Bent.   

Abstract

BACKGROUND: The late neurotoxic effects of bone marrow transplantation (BMT) on cognitive functioning and quality of life (QOL) were investigated in a consecutively treated cohort of long-term adult survivors.
METHODS: Progression-free patients treated with BMT or peripheral stem cell grafts for a hematologic malignancy at least 2 years before study participation were examined with a comprehensive battery of neuropsychological tests and questionnaires for QOL and mood states. The results of the neuropsychological tests were compared with healthy population norms.
RESULTS: Forty patients were included, 87.5% of whom had undergone an allogeneic transplantation. All received total body irradiation up to 12 Gy (in two fractions). Assessment took place 22-82 months after BMT. Mild to moderate cognitive impairment was found in 24 patients (60%). Compared with healthy population norms, selective attention and executive function, information processing speed, verbal learning, and verbal and visual memory were most likely to be affected. The mean score for the total patient group revealed that these patients scored significantly lower on the information processing speed task compared with expected scores obtained from the normal population. The main predictors for poor neuropsychological performance were fatigue, global health, and educational level. Other correlations with moderate to severe cognitive impairment were subjective cognitive complaints, physical functioning, social functioning, overall mood states, and employment status.
CONCLUSIONS: These data indicate that BMT may lead to cognitive complaints and late cognitive deficits in long-term adult survivors. Cognitive functioning should therefore be used as an outcome parameter in BMT studies. Copyright 2002 American Cancer Society.

Entities:  

Mesh:

Year:  2002        PMID: 12115332     DOI: 10.1002/cncr.10627

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  35 in total

1.  Engaging Patients in Setting a Patient-Centered Outcomes Research Agenda in Hematopoietic Cell Transplantation.

Authors:  Linda J Burns; Beatrice Abbetti; Stacie D Arnold; Jeffrey Bender; Susan Doughtie; Areej El-Jawahiri; Gloria Gee; Theresa Hahn; Mary M Horowitz; Shirley Johnson; Mark Juckett; Lakshmanan Krishnamurit; Susan Kullberg; C Fred LeMaistre; Alison Loren; Navneet S Majhail; Elizabeth A Murphy; Doug Rizzo; Alva Roche-Green; Wael Saber; Barry A Schatz; Kim Schmit-Pokorny; Bronwen E Shaw; Karen L Syrjala; D Kathryn Tierney; Christina Ullrich; David J Vanness; William A Wood; Ellen M Denzen
Journal:  Biol Blood Marrow Transplant       Date:  2018-02-03       Impact factor: 5.742

2.  A mixed methods analysis of perceived cognitive impairment in hematopoietic stem cell transplant survivors.

Authors:  Lisa M Wu; Nadia Kuprian; Krista Herbert; Ali Amidi; Jane Austin; Heiddis Valdimarsdottir; Christine Rini
Journal:  Palliat Support Care       Date:  2019-08

3.  Self-efficacy beliefs mediate the relationship between subjective cognitive functioning and physical and mental well-being after hematopoietic stem cell transplant.

Authors:  Lisa M Wu; Jane Austin; Jada G Hamilton; Heiddis Valdimarsdottir; Luis Isola; Scott Rowley; Rachel Warbet; Gary Winkel; William H Redd; Christine Rini
Journal:  Psychooncology       Date:  2011-07-08       Impact factor: 3.894

Review 4.  Sleep disruption in hematopoietic cell transplantation recipients: prevalence, severity, and clinical management.

Authors:  Heather S L Jim; Bryan Evans; Jiyeon M Jeong; Brian D Gonzalez; Laura Johnston; Ashley M Nelson; Shelli Kesler; Kristin M Phillips; Anna Barata; Joseph Pidala; Oxana Palesh
Journal:  Biol Blood Marrow Transplant       Date:  2014-04-18       Impact factor: 5.742

5.  Pretransplantation Cognitive Dysfunction in Advanced-Age Hematologic Cancers: Predictors and Associated Outcomes.

Authors:  James C Root; Claudine Campbell; Xiomara Rocha-Cadman; Nicole Kasven-Gonzalez; Molly Maloy; Jessica Flynn; Sean M Devlin; Ann A Jakubowski
Journal:  Biol Blood Marrow Transplant       Date:  2020-05-21       Impact factor: 5.742

6.  Predictors of the trajectory of cognitive functioning in the first 6 months after allogeneic hematopoietic stem cell transplantation.

Authors:  Samantha J Mayo; Hans A Messner; Sean B Rourke; Doris Howell; J Charles Victor; Jeffrey H Lipton; J Kuruvilla; Vikas Gutpa; Dennis Dong Hwan Kim; Fotios V Michelis; Kelly Metcalfe
Journal:  Bone Marrow Transplant       Date:  2019-11-19       Impact factor: 5.483

Review 7.  Psychological Considerations in Hematopoietic Stem Cell Transplantation.

Authors:  Hermioni L Amonoo; Christina N Massey; Melanie E Freedman; Areej El-Jawahri; Halyna L Vitagliano; William F Pirl; Jeff C Huffman
Journal:  Psychosomatics       Date:  2019-02-14       Impact factor: 2.386

Review 8.  National Institutes of Health Hematopoietic Cell Transplantation Late Effects Initiative: The Patient-Centered Outcomes Working Group Report.

Authors:  Margaret Bevans; Areej El-Jawahri; D Kathryn Tierney; Lori Wiener; William A Wood; Flora Hoodin; Erin E Kent; Paul B Jacobsen; Stephanie J Lee; Matthew M Hsieh; Ellen M Denzen; Karen L Syrjala
Journal:  Biol Blood Marrow Transplant       Date:  2016-09-19       Impact factor: 5.742

Review 9.  Neuropsychological sequelae of non-central nervous system cancer and cancer therapy.

Authors:  Jeffrey S Wefel; Mariana E Witgert; Christina A Meyers
Journal:  Neuropsychol Rev       Date:  2008-04-16       Impact factor: 7.444

10.  Acute cognitive impairment in patients with multiple myeloma undergoing autologous hematopoietic stem cell transplant.

Authors:  Desiree Jones; Elisabeth G Vichaya; Xin Shelley Wang; Mary H Sailors; Charles S Cleeland; Jeffrey S Wefel
Journal:  Cancer       Date:  2013-09-16       Impact factor: 6.860

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.